Information letter to healthcare professionals regarding the medicinal product ANALGIN. Important information on minimizing the serious consequences of the known risk of agranulocytosis associated with the use of medicinal products containing metamizole

24.11.2025 414 views

Інформаційний лист до спеціалістів системи охорони здоров’я щодо лікарського засобу АНАЛЬГІН. Важлива інформація з мінімізації серйозних наслідків відомого ризику агранулоцитозу при застосуванні лікарських засобів, що містять метамізол (metamizole)PDF · 343 КБ

Завантажити

Information letter to healthcare professionals regarding the medicinal product ANALGIN. Important information on minimizing the serious consequences of the known risk of agranulocytosis associated with the use of medicinal products containing metamizole

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to healthcare professionals regarding the medicinal product ANALGIN. Important information on minimizing the serious consequences of the known risk of agranulocytosis associated with the use of medicinal products containing metamizole

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration